PMID- 27893423
OWN - NLM
STAT- MEDLINE
DCOM- 20180309
LR  - 20181202
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 7
IP  - 52
DP  - 2016 Dec 27
TI  - Efficacy and safety of icotinib in treating non-small cell lung cancer: a 
      systematic evaluation and meta-analysis based on 15 studies.
PG  - 86902-86913
LID - 10.18632/oncotarget.13509 [doi]
AB  - Icotinib is a new epidermal growth factor receptor (EGFR) tyrosine kinase 
      inhibitor (TKI) that developed and used in China; this work was to evaluate its 
      efficacy and safety in treating non-small cell lung cancer (NSCLC). Clinical 
      studies evaluating the efficacy and safety of icotinib in treating NSCLC were 
      identified from the databases of Medline, Web of Science, Embase and Cochrance 
      Library. Pooled efficacy and safety of icotinib were calculated through a series 
      of predefined search strategies. A total of 15 studies with 2,304 patients were 
      involved in this study. The overall response rate (ORR) and disease control rate 
      (DCR) of icotinib were 40.99% (95% CI: 33.77% to 48.22%) and 77.16% (95% CI: 
      51.43% to 82.31%). The pooled progression-free survival (PFS) and overall 
      survival (OS) were 7.34 months (95% CI: 5.60 to 9.07) and 14.98 months (95% CI: 
      9.78 to 20.18). Patients with EGFR mutations exhibited better ORR (OR = 3.67, p < 
      0.001), DCR (OR = 1.39, p = 0.001) and PFS (11.0 +/- 0.76 vs. 1.97 +/- 0.82 months). 
      Moreover, patients with rash had a higher ORR (OR = 2.14, p = 0.001) than those 
      without rash. The common adverse effects (AEs) included skin rash (31.4%), 
      diarrhea (14.2%), pruritus (6.7%) and hepatic toxicity (3.8%) and most of them 
      were well tolerated. In conclusion, Icotinib is an effective and well tolerated 
      regimen for Chinese patients with advanced NSCLC. Further randomized trials with 
      large population are required to provide stronger evidence for icotinib in 
      treating NSCLC.
FAU - Biaoxue, Rong
AU  - Biaoxue R
AD  - Department of Respiratory Medicine, First Affiliated Hospital, Xi'an Medical 
      University, Xi'an, China.
FAU - Hua, Liu
AU  - Hua L
AD  - Department of Respiratory Medicine, Gansu Provincial Hospital, Lanzhou, China.
FAU - Wenlong, Gao
AU  - Wenlong G
AD  - Department of Statistics and Epidemiology, Medical College, Lanzhou University, 
      Lanzhou, China.
FAU - Shuanying, Yang
AU  - Shuanying Y
AD  - Department of Respiratory Medicine, Second Affiliated Hospital, Xi'an Jiaotong 
      University, Xi'an, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Crown Ethers)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinazolines)
RN  - 9G6U5L461Q (icotinib)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics
MH  - Crown Ethers/adverse effects/*therapeutic use
MH  - Diarrhea/chemically induced
MH  - Disease-Free Survival
MH  - ErbB Receptors/genetics
MH  - Exanthema/chemically induced
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/genetics
MH  - Mutation
MH  - Protein Kinase Inhibitors/adverse effects/therapeutic use
MH  - Pruritus/chemically induced
MH  - Quinazolines/adverse effects/*therapeutic use
MH  - Treatment Outcome
PMC - PMC5349962
OTO - NOTNLM
OT  - NSCLC
OT  - efficacy
OT  - icotinib
OT  - meta-analysis
OT  - non-small cell lung cancer
COIS- CONFLICTS OF INTEREST The authors declare no conflicts of interest.
EDAT- 2016/11/29 06:00
MHDA- 2018/03/10 06:00
PMCR- 2016/12/27
CRDT- 2016/11/29 06:00
PHST- 2016/08/23 00:00 [received]
PHST- 2016/11/08 00:00 [accepted]
PHST- 2016/11/29 06:00 [pubmed]
PHST- 2018/03/10 06:00 [medline]
PHST- 2016/11/29 06:00 [entrez]
PHST- 2016/12/27 00:00 [pmc-release]
AID - 13509 [pii]
AID - 10.18632/oncotarget.13509 [doi]
PST - ppublish
SO  - Oncotarget. 2016 Dec 27;7(52):86902-86913. doi: 10.18632/oncotarget.13509.